BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Asami K, Atagi S. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. World J Clin Oncol 2014; 5(4): 646-659 [PMID: 25302168 DOI: 10.5306/wjco.v5.i4.646]
URL: https://www.wjgnet.com/2218-4333/full/v5/i4/646.htm
Number Citing Articles
1
Shanthi Kanthala, Sandeep Pallerla, Seetharama Jois. Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsFuture Oncology 2015; 11(5): 865 doi: 10.2217/fon.14.312
2
Haijian Wu, Yan Liu, Xiao Ou Shu, Qiuyin Cai. MiR-374a suppresses lung adenocarcinoma cell proliferation and invasion by targetingTGFAgene expressionCarcinogenesis 2016; 37(6): 567 doi: 10.1093/carcin/bgw038
3
BO ZHOU, JUN NIE, WEIDONG YANG, CHENHONG HUANG, YE HUANG, HONGFEI ZHAO. Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patientsOncology Letters 2016; 11(2): 1413 doi: 10.3892/ol.2015.4066
4
Christina Stache, Christiane Bils, Rudolf Fahlbusch, Jörg Flitsch, Michael Buchfelder, Harald Stefanits, Thomas Czech, Udo Gaipl, Benjamin Frey, Rolf Buslei, Annett Hölsken. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivinNeurosurgical Focus 2016; 41(6): E14 doi: 10.3171/2016.9.FOCUS16316
5
Kai Wu, Jiachen Li, Yu Qi, Chunyang Zhang, Dengyan Zhu, Donglei Liu, Song Zhao. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3pBiomedicine & Pharmacotherapy 2019; 116: 108995 doi: 10.1016/j.biopha.2019.108995
6
STEFAN HARTMANN, ROMAN C. BRANDS, NORA KÜCHLER, ANDREAS FUCHS, CHRISTIAN LINZ, ALEXANDER C. KÜBLER, URS D.A. MÜLLER-RICHTER. Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancerOncology Letters 2015; 10(2): 1211 doi: 10.3892/ol.2015.3345
7
Keara L. Redmond, Anastasia Papafili, Mark Lawler, Sandra Van Schaeybroeck. Overcoming Resistance to Targeted Therapies in CancerSeminars in Oncology 2015; 42(6): 896 doi: 10.1053/j.seminoncol.2015.09.028
8
Xiaoyan Ma, Min Shan, Yunlong Lu. Design and Synthesis of Gefitinib Derivatives as Potential Drugs fo r Cancer Treatment: Antiproliferative Activity, Molecular Docking, and ADMET PredictionLetters in Drug Design & Discovery 2024; 21(9): 1555 doi: 10.2174/1570180820666230810164118
9
Nina Shaban, Dmitri Kamashev, Aleksandra Emelianova, Anton Buzdin. Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical ApplicationsCells 2023; 13(1): 47 doi: 10.3390/cells13010047
10
L Jin, Y Liu, X Wang, X Qi. Immunohistochemical analysis and comparison of napsin A, TTF1, SPA and CK7 expression in primary lung adenocarcinomaBiotechnic & Histochemistry 2018; 93(5): 364 doi: 10.1080/10520295.2018.1444790
11
Xuefeng Zhou, Jialong Guo, Yanmei Ji, Gaofeng Pan, Tao Liu, Hua Zhu, Jinping Zhao. Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung AdenocarcinomaMolecular Cancer Research 2016; 14(5): 448 doi: 10.1158/1541-7786.MCR-15-0480
12
Bin Wang, Lixiao Liu, Jinting Wu, Xiaolu Mao, Zhen Fang, Yingyu Chen, Wenfeng Li. Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell CarcinomaFrontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.711142
13
Jinsong Li, Huayun Deng, Meichun Hu, Yuanzhang Fang, Amanda Vaughn, Xiaopan Cai, Leqin Xu, Wei Wan, Zhenxi Li, Shijie Chen, Xinghai Yang, Song Wu, Jianru Xiao. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFROncotarget 2015; 6(9): 6749 doi: 10.18632/oncotarget.3155
14
Karla A. Ruiz-Ceja, Yolanda I. Chirino. Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detectionBiomedicine & Pharmacotherapy 2017; 90: 24 doi: 10.1016/j.biopha.2017.03.018